Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1991-03-19
1993-06-29
Saunders, David
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435975, G01N 3353
Patent
active
052233995
ABSTRACT:
Certain patients undergoing clozapine drug therapy may be vulnerable to agranulocytosis. It has been found that agranulocytosis vulnerability is correlated with the presence of HLA antigens B38, DR4 and DQw3. Accordingly, a method is provided for detecting such patients, and an HLA kit is provided.
REFERENCES:
A. R. Ahmed et al, Proc. Natl. Acad. Sci., 87, 7658-7662, 1990.
J. A. Lieberman et al, Arch. Gen. Psychiatry, 47, 945-948, 1990.
E. L. Milford et al, in B. Dupont (ed.), Immunobiology of HLA, vol. I, Springer-Verlag, New York, 1987, pp. 93-106.
Lieberman Jeffrey A.
Yunis Edmond J.
Borovian Joseph J.
Dana-Farber Cancer Institute
Honor Robert S.
Kassenoff Melvyn M.
Long Island Jewish Medical Center
LandOfFree
Agranolocytosis screening procedure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agranolocytosis screening procedure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agranolocytosis screening procedure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1754575